|Articles|March 7, 2022
Daily Medication Pearl: Aggrenox (Aspirin/ER, Dipyridamole)
Author(s)Saro Arakelians, PharmD
Aggrenox is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
Advertisement
Medication Pearl of the Day: Aggrenox (Aspirin/ER, Dipyridamole)
Indication: Aggrenox is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
Insight:
- Dosing: One capsule twice daily (morning and evening) with or without food.
- Dosage forms: Capsule 25 mg aspirin/200 mg extended-release dipyridamole.
- Adverse events (AEs): The most frequently reported AEs (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea.
- Mechanism of action: The antithrombotic action of Aggrenox is the result of the additive antiplatelet effects of dipyridamole and aspirin.
- Manufacturer: Boehringer Ingelheim
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
2
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5